L-Ornithine and Cancer

L-Ornithine and Cancer: What the Evidence Shows

Ornithine is sold over the counter for sleep, exercise recovery and liver support. It is also the carrier the urea cycle runs on and the direct precursor of the polyamines that tumours need in order to divide. The research literature points in both directions at once, and no therapeutic trial of ornithine in people with cancer has ever been run. This page sets out what has actually been tested.

Most people taking ornithine are taking it for sleep, for exercise recovery, or because they have read that it supports the liver. It is cheap, it is a normal constituent of the human body, and it is sold without a prescription almost everywhere.

It is also one of the more interesting molecules in cancer metabolism, for a reason that has nothing to do with any of those uses: it sits at a fork, and the two branches lead in opposite directions. One disposes of nitrogen. The other builds the polyamines that rapidly dividing cells depend on. Nothing in a capsule chooses between them.

The honest summary is that ornithine's effects in cancer are context-dependent and not currently predictable. Direct administration reduced tumour burden in particular colorectal and liver cancer mouse models. Other direct experiments found tumour promotion, no effect at all, or expansion of immunosuppressive cells. A literature going back to 1985 reports that ornithine suppresses cytotoxic T lymphocyte activation. And no trial has ever tested standalone ornithine as a cancer treatment in a human being. The evidence supports neither “ornithine is anticancer” nor “ornithine feeds cancer.”
About the sourcing on this page. The experimental inventory behind it is a structured evidence map covering animal experiments, cell culture, immune-cell assays, isotope tracing, computational models, human metabolomics, genetic analyses and indexed trial-registry searches. It is not a registered systematic review, and it carries no guarantee that every relevant publication was retrieved. Where a finding rests on an abstract rather than a full text, or where a dose could not be recovered from the paper, this page says so rather than smoothing it over.

One Molecule, Two Enzymes, Opposite Consequences

Ornithine transcarbamylase condenses ornithine with carbamoyl phosphate to make citrulline, and the nitrogen heads toward urea and out of the body. Ornithine decarboxylase takes the same molecule and strips its carboxyl group, producing putrescine, then spermidine, then spermine — the polyamines, without which no cell divides quickly.

ODC is one of the most studied targets in oncology. Its inhibitor, DFMO or eflornithine, is an approved drug in neuroblastoma. That is the measure of how seriously the polyamine branch is taken as a cancer dependency.

Ornithine sits at a branch point between urea and polyamines Ornithine can go two ways. Ornithine transcarbamylase condenses it with carbamoyl phosphate to make citrulline and then urea, so the nitrogen leaves the body. Ornithine decarboxylase instead removes the carboxyl group to make putrescine, then spermidine and spermine, the polyamines that support rapid cell division and feed tumour proliferation. The same molecule, two enzymes, opposite consequences, and nothing in a capsule chooses between them. One molecule, two enzymes Nothing in a capsule chooses between them Ornithine OTC — the route you want + carbamoyl phosphate citrulline, then urea nitrogen leaves the body ODC — the leak decarboxylated to putrescine spermidine, then spermine feeds rapid cell division DFMO blocks the right-hand branch. It has never been combined with the left. Ornithine sits at a branch point between urea and polyamines Stacked version. Ornithine goes either to ornithine transcarbamylase, making citrulline and urea so nitrogen leaves the body, or to ornithine decarboxylase, making putrescine, spermidine and spermine, which feed rapid cell division. DFMO blocks the second branch. One molecule, two enzymes Ornithine OTC — the route you want citrulline, then urea nitrogen leaves the body ODC — the leak putrescine, spermidine, spermine feeds rapid cell division
In a cirrhotic patient without cancer, only the left branch matters. In a cancer patient, both do.

Which branch dominates is not a property of ornithine. It is a property of the cell receiving it, and tumours are not ordinary cells. Lee and colleagues showed in Nature in 2023 that pancreatic ductal adenocarcinoma runs ornithine aminotransferase in its forward direction — an activity normally confined to infancy — to manufacture ornithine from glutamine, because arginine is depleted in the tumour microenvironment and the usual supply route is closed. Silencing or inhibiting OAT collapsed the polyamine pools and suppressed tumour growth.

Read that the other way round. A tumour under arginine restriction will reactivate a developmental enzyme and build ornithine from scratch, because it cannot get enough. That is not the behaviour of a cell with substrate to spare. Ornithine supply is something some tumours work for.

Not all tumours obtain it the same way. Work on neuroblastoma published in 2025 used isotope tracing and quantitative modelling to identify circulating ornithine as an important tumour precursor, with much of the arginine-to-ornithine conversion happening outside the tumour. Pancreatic cancer emphasises local synthesis; neuroblastoma draws on the circulation. Where a tumour gets its ornithine determines whether what you swallow can reach it.

Two Models, Both Involving Ammonia

These are the results that make ornithine interesting in oncology, and they are real.

Colorectal cancer, 2023

Bell and colleagues found ammonia accumulating in colorectal tumours and driving CD8 T cells into exhaustion. Daily intraperitoneal L-ornithine monohydrochloride reduced MC38 and CT26 syngeneic tumour growth and liver-metastatic burden in mice, with tumour ammonia and proliferation markers declining. The benefit disappeared in nude mice and after CD8 depletion, which is the control that makes the mechanism immune-dependent rather than direct.

Liver cancer, 2024

Elaimy and colleagues, having shown across 48,476 cirrhosis patients that baseline serum ammonia predicts who develops hepatocellular carcinoma, treated Myc/p53-driven HCC-bearing mice with ornithine monohydrochloride. Liver weight and tumour burden fell, along with tumour ammonia, CD44 and SLC4A11 expression, and ALDH activity. A separate graft experiment in immunodeficient mice supported reduced tumour weight under high-ammonia conditions.

Two qualifications belong immediately next to those results rather than at the end of the page.

In Bell's more aggressive model, ornithine alone did not significantly improve survival (P = 0.07). The tumour-growth and metastasis results stand; the survival result in the TripleMut model did not reach significance for ornithine as a single agent. Results from its immunotherapy-combination arms cannot be used to support ornithine on its own.
Neither paper reports a dose that can be translated to a person. Bell's figure legend specifies “daily intraperitoneal injection of 10 mM ornithine.” Elaimy's methods state that “ornithine was delivered by i.p. injection in C57BL/6J mice or s.c. implantation in NSG mice at a concentration of 20 mM.” Those are concentrations, not doses. Without a volume per injection there is no mg/kg, and without mg/kg there is no human-equivalent dose. Assume the standard mouse intraperitoneal volume of 5 to 10 mL/kg and apply the usual body-surface-area conversion and you land somewhere around 30 to 150 mg a day for a 70 kg person — but every digit of that rests on a volume neither paper supplies. It is a sensitivity analysis, not a figure.

Promotion, Nothing, and a Dose Reversal

This is the part of the literature least represented in popular writing about ornithine, and it is the part that most changes the picture. Each of these is a direct ornithine experiment, not an inference from a related compound.

Study Exposure Result
Ushmorov, Hack & Dröge, 1999
MCA-105 fibrosarcoma, cancer cachexia model
0.2 mg/day i.p. for one week, versus 20 mg/day The low dose improved muscle respiratory-chain activity and redox measures with only marginal tumour effects. The hundred-fold higher dose significantly increased tumour size (P < 0.05).
Tharp et al., 2024
Nature Cancer; orthotopic PyMT breast cancer
2 g/kg daily oral gavage Did not independently alter tumour growth. In a myeloid-Tgfbr2-knockout experiment, ornithine removed the tumour-mass reduction the knockout produced. In culture, 0.5–4.5 mM impaired CD8 metabolic function and viability and reduced killing of tumour organoids.
Yuan et al., 2024
Cell Discovery; gastric cancer xenograft
Separately administered ornithine arm Promoted xenograft growth. Dose, route, schedule and sample size for that arm could not be verified from the inaccessible supplement.
Pan et al., 2026
Nature Communications; 4T1 bone metastasis
100 µM in culture; 10 mg/kg i.p. daily for 14 days Increased PMN-MDSC proportions in mouse bone marrow and human PBMC cultures, and in bone-metastatic tumours in vivo. Ornithine did not directly increase cancer-cell colony formation or migration.
Gonzalez & Byus, 1991
Two-stage skin carcinogenesis, 19 weeks
2% ornithine in drinking water Dietary arginine restriction reduced papillomas by about 40–50%. Ornithine in the drinking water reversed that reduction. It was not shown to initiate cancer independently.

Direct ornithine administration experiments with null or adverse outcomes. The Ushmorov result is the only published dose-reversal within a single model.

The Ushmorov finding deserves to be read twice, because it is the single most relevant experiment on this page for anyone taking a supplement. Same molecule, same model, same route, same week. At one dose it improved markers of cachexia. At a hundred times that dose it made tumours bigger. That is not a reason to pick the low dose — a single model does not establish a safe threshold, and the human equivalents of either figure are unknown. It is a reason to stop treating “ornithine” as a thing with a direction.

Parenteral nutrition studies, which are often cited and should not be

A set of studies from the 1990s substituted ornithine for arginine in total parenteral nutrition in tumour-bearing rats, and found lower tumour weights with ornithine than with arginine. In Grossie's 1996 experiment, eight-day tumours weighed 14.1 ± 3.3 g with arginine, 12.7 ± 1.4 g with citrulline, 8.8 ± 2.0 g with ornithine and 8.9 ± 2.1 g with ordinary chow.

Notice the chow column. Ornithine substitution avoided the extra growth that arginine-containing parenteral nutrition induced. It did not reduce tumours below the ordinary-diet control. These are arginine-removal experiments with ornithine as the replacement, not ornithine-addition experiments, and the two cannot be read as the same thing. Group sizes were four to six animals.

A Forty-Year-Old Problem That Has Not Been Resolved

If ornithine helps in cancer by relieving an immune brake, as the colorectal work suggests, then it is worth knowing that a separate literature reports ornithine doing the opposite to T cells directly.

Study Concentration Finding
Dröge et al., 1985
J Immunol
9 mM Nearly abolished early cytotoxic T lymphocyte activation in culture; adding it later had less effect. D-ornithine did not reproduce the effect, so it is not a generic osmotic or nitrogen artefact.
Jänicke & Dröge, 1985 9 mM Suppressed CTL generation in mixed leukocyte culture. Reversibility and limited general toxicity argued against simple killing of responder cells.
Susskind et al., 1986 10 mM Arrested CTL development without killing precursors; suppressor-cell activity persisted.
Susskind et al., 1991 not recovered CTL differentiation inhibited, but lymphokine-activated killer activity against P815 and YAC-1 targets was not suppressed. Ornithine does not inhibit all effector populations equally.
Tharp et al., 2024
Nature Cancer
0.5, 1.5, 4.5 mM At increasing ornithine-to-arginine ratios, impaired CD8 metabolic function and viability; higher ornithine reduced killing of tumour organoids. The modern replication of the 1980s finding, in a cancer model.
Menjivar et al., 2023
eLife
1.15 mM, 72 h In arginine-free medium, partially restored CD8 proliferation but not activation. No enhancement in arginine-replete medium.

Direct ornithine effects on T cells. Most of the older work used allogeneic stimulation rather than a tumour model.

Two honest caveats. The 9 to 10 mM concentrations in the 1980s work are high — far above anything ordinary oral supplementation would be expected to produce in tissue — and several of those records rest on abstracts rather than full texts. But Tharp's 2024 experiments saw impairment from 0.5 mM upward, in a cancer model, published in a leading journal, and the effect there tracked the ratio of ornithine to arginine rather than ornithine alone. That is a mechanism which supplementation could plausibly move.

So the immune story has two directions in it, not one. Removing ammonia from a tumour microenvironment may release a brake on T cells. Raising the local ornithine-to-arginine ratio may apply a different one. Nobody has measured both endpoints in the same experiment, and until somebody does, “ornithine supports anti-tumour immunity” is a hypothesis with published evidence against it as well as for it.

And the myeloid compartment

In tumour-associated macrophages, ornithine is converted by ODC into polyamines, and the polyamines are required for M2 polarisation — they drive expression of M2 genes and suppress M1 activation. Pan's 2026 work adds the neutrophilic arm: 10 mg/kg daily expanded PMN-MDSCs, the suppressive myeloid population, in bone marrow and bone-metastatic tumours. The polyamine problem is not only a tumour-cell problem.

There Is No Therapeutic Trial. There Is a Tracer Study.

This is the shortest section on the page and the most important one.

No trial demonstrating anticancer efficacy of standalone ornithine in people has been identified — not a failed one, none. The only documented human administration in this context is a 1980 diagnostic tracer study: ten untreated cancer patients and twelve volunteers received 8 µCi of L-[1-14C]ornithine hydrochloride, 160 nanomoles intravenously. Mean labelled-CO2 recovery at 2.5 hours was 23.0% in patients versus 12.6% in controls. One hundred and sixty nanomoles is a tracer quantity. It measures whole-body label metabolism. It is not a treatment, and it was never intended as one.

Registry checks used indexed ClinicalTrials.gov, UMIN and ISRCTN searches rather than a live registry export, so this is a bounded search finding rather than proof of universal absence. But the absence is large and consistent.

What human ornithine measurements show instead

There is a substantial observational literature measuring ornithine concentrations in people with cancer. It does not converge.

Cancer Study and size Direction
Breast Zhang 2020; 735 cases / 735 controls Higher ornithine, lower odds. OR per SD 0.88 (0.79–0.97). But 95% of controls had benign breast lumps, and samples were taken after disease developed.
Breast Hu 2016; 33 / 32 Ornithine higher in cancer. Opposite direction to the larger study.
Colorectal Rothwell 2023; EPIC, 654 future cases / 654 controls, prospective No significant association. OR per SD 0.88 (0.69–1.13); excluding the first ten years, 1.03 (0.78–1.36). The best-designed entry in the table, and it is null.
Colorectal Hu 2021 (63 / 63) versus Coradduzza 2023 (50 / 52) Lower in cancer, and higher in cancer, respectively. Directly contradictory.
Prostate Ladurner 2025; 1,078 men undergoing biopsy Higher in clinically significant disease, 63.7 versus 50.3 µM. The reported 0.84 AUC belongs to a multi-metabolite model, not to ornithine.
Bladder Liu 2024 (95 / 96) versus Giorgione 2026 (14 patients) Higher ornithine with lower odds in one; higher than controls in the other. Contradictory again.
AML 1999 series; 40 untreated / 24 controls Higher in cancer: 108.7 ± 5.8 versus 78 ± 6 µM, P < 0.001.

Circulating ornithine in cancer. Several additional entries in the underlying inventory did not survive multiple-testing correction.

Why none of this tells you what to do. Blood, urine, tumour interstitial fluid and intracellular ornithine are different compartments. A low circulating level may reflect consumption, nutritional status or organ function. A high level may reflect production, impaired utilisation, or impaired clearance. Direction of association, in samples taken after disease has developed, cannot establish whether raising or lowering ornithine would change an outcome. One Mendelian randomisation screen of 1,400 metabolites found genetically proxied ornithine associated with lower oesophageal cancer odds — a nominal, exploratory result from a multiplicity-heavy screen, and a lifelong genetically influenced concentration is not the same thing as taking a capsule.

Three Preparations, and They Are Not Interchangeable

L-ornithine-L-aspartate (LOLA)

A salt of two amino acids, marketed for hepatic encephalopathy since the 1990s and available on prescription across much of Europe, Asia and Latin America. It is not FDA-approved in the United States. It works on two fronts: ornithine enters the urea cycle as the OTC substrate, and both amino acids feed glutamate, which skeletal muscle uses to fix ammonia into glutamine via glutamine synthetase. In a cirrhotic patient whose liver cannot make urea, the muscle route matters more than the hepatic one.

Ornithine phenylacetate

A deliberate two-part design. Ornithine drives glutamine synthesis; phenylacetate then conjugates that glutamine into phenylacetylglutamine, which the kidney excretes. The nitrogen leaves the body rather than being parked in a pool that can release it again.

L-ornithine on its own

Sold as a sleep and bodybuilding supplement, typically at 500 mg to 2 g. This is the one people can buy, and it is the one with no clinical trial evidence of any kind in liver disease or cancer.

The dose gap cuts both ways, and that is the problem. In a 2024 randomised trial, LOLA was given at 30 g per day — either as a continuous infusion or as 5 g sachets every four hours. A typical capsule contains 500 mg, so someone taking two a day is at roughly three per cent of a clinical dose of a different molecule studied in a different disease. Measured against the mouse cancer experiments, though, that same 500 mg capsule is several times the estimated human-equivalent dose. The two reference points disagree by three orders of magnitude about whether supplement doses are negligible or already high, and nobody has established which scale any cancer-relevant effect would belong to.

One practical finding worth having from that trial: 40 patients with overt hepatic encephalopathy randomised to intravenous or oral LOLA alongside standard care showed no difference between routes. Ammonia fell by 55.4 ± 32.58 µM on the drip and 60.75 ± 13.82 µM by mouth (p = 0.511), with both groups improving. For a drug whose oral bioavailability has long been questioned, that is reassuring as far as it goes — though 40 patients is 40 patients.

The Liver Evidence Is Weaker Than It Looks

Ornithine's good name comes almost entirely from hepatology, so it is worth seeing what that evidence actually says.

The Cochrane review is the one to read. Thirty-six trials, outcome data from 29 trials and 1,891 participants. Its finding: all apparent benefits of LOLA disappear when the analysis is restricted to trials at low risk of bias. Certainty of evidence was graded very low throughout. Seventeen trials were industry-funded, and ten completed trials were unpublished and unavailable to the reviewers.

And the enthusiastic literature has a narrow authorship. The 2019 meta-analysis most often cited for LOLA in prevention of overt encephalopathy — six trials, 384 patients, RR 0.38 (0.23–0.62) — is a single-author paper by Roger Butterworth, who is also co-author of the review making the case for LOLA in fatty liver disease. That is not an accusation of anything. It is a reason to read the primary trials rather than the reviews, and to notice when a field's advocacy rests on a small number of people.

In fatty liver, thinner still

The human data for LOLA in NAFLD, as assembled by its advocates, amounts to: an uncontrolled observational study of 463 patients given oral LOLA for 30 to 90 days, reporting falls in ASAT of 46.6%, ALT of 40.6% and γ-GT of 60.8%; an open-label randomised multicentre study in 72 NASH patients showing a dose-related ALT reduction over 12 weeks; and an uncontrolled study of 78 patients looking at hepatic microcirculation.

Transaminases in fatty liver fall with weight loss, with alcohol cessation, with regression to the mean, and with the simple fact of being enrolled in a study and told to take something. An uncontrolled 40–60% drop is close to uninterpretable. There is no blinded, placebo-controlled trial of LOLA in fatty liver disease with histological endpoints.

The best test anyone has run

STOP-HE was a phase 2b study of intravenous ornithine phenylacetate in 231 hospitalised cirrhotic patients with elevated ammonia and overt hepatic encephalopathy, at three dose levels, against placebo, on top of standard care. Properly powered, properly designed, in exactly the population where ammonia is the agreed cause of the problem.

It missed its primary endpoint. Time to clinical improvement was 47 hours against 64 on placebo, p = 0.129. Ammonia fell significantly — 30.8 versus 11.8 µM, p = 0.017. The drug was safe and well tolerated, with fewer deaths in the treatment arm than on placebo, 11 versus 15, and the higher dose groups did better than the lowest. There is a real signal in there.

We can lower ammonia. We have not yet shown that lowering it changes clinical outcomes — not even in hepatic encephalopathy, the one disease where essentially everybody agrees ammonia is the cause.

What Follows From All This, and What Does Not

Ornithine is cheap, sold without a prescription, and now has research threads pointing at it in diseases that frighten people. Everything about that combination invites someone reading this to go and buy some, or to stop. So let me be precise about what the evidence does and does not support.

What is established

Ornithine-based drugs lower ammonia in people. That much is solid, by both routes, in the thousands of patients who have taken LOLA and in the 231 of STOP-HE. Ornithine is a normal constituent of the body and of the diet, and healthy-volunteer tolerance studies exist.

What is not

That lowering ammonia improves any clinical outcome — the best-designed trial missed its endpoint. That ornithine has any effect on cancer in humans, in either direction. That the mouse results generalise. That any particular supplement dose is either effective or safe in the presence of a tumour.

What points the wrong way

Direct tumour promotion in a gastric model. Reversal of a protective dietary effect in skin carcinogenesis. Expansion of suppressive myeloid cells. Impaired CD8 function at concentrations from 0.5 mM. And a hundred-fold dose increase turning a cachexia benefit into significantly larger tumours in the same model.

What nobody knows

Which tumour and host features predict benefit versus harm. What oral supplementation does to ornithine concentrations inside a tumour. Whether the ammonia-clearance effect and the polyamine effect can be separated. Whether any of this applies at sleep-supplement doses.

If you have cancer, this page is not a reason to start taking ornithine, and it is not a reason to panic if you have been taking it. There is no human trial in cancer of any kind. The animal results run in both directions, with tumour promotion reported in at least two models and a clear dose reversal in a third. The molecule feeds the polyamine pathway that tumours depend on, and some tumours will go to considerable lengths to make more of it. Nothing on this page distinguishes a person who would benefit from one who would be harmed, because nobody has done the work that would allow it. Anyone taking ornithine, or considering it, during cancer treatment should tell the oncology team that knows their case — partly for the obvious reason, and partly because the honest answer that team will give is that the evidence does not exist yet, which is itself worth hearing from someone who can see your scans.

If you are taking ornithine for sleep or training and have no cancer diagnosis, none of the above is an argument that you are harming yourself. It is an argument that the confident claims made for ornithine in cancer — in both directions — are running well ahead of what has been tested.

What Would Actually Settle This

  • Reproducible dose–response within a single model. The Ushmorov reversal is one experiment from 1999. Whether a therapeutic window exists, and where, has not been re-tested in the twenty-six years since.
  • Both immune endpoints measured together. One experiment measuring ammonia relief of T cell exhaustion and the ornithine-to-arginine ratio effect on CD8 function, in the same animals. The two literatures have never met.
  • What oral dosing does to tumour interstitial ornithine. Every mouse experiment used injection. Nobody has measured what swallowing it does to concentrations where a tumour sits.
  • Ornithine with ODC blockade. Supply the carrier and block the polyamine branch with DFMO, which is approved in neuroblastoma so the toxicology exists. If the polyamine branch is what limits ornithine's usefulness, blocking it should turn a modest effect into a large one. If it changes nothing, the polyamine worry can be set down. The combination appears never to have been tested.
  • Any human trial at all. Standalone oral ornithine, with plasma and where possible tumour-interstitial measurement, in a defined cancer population, with clinically relevant endpoints and investigators independent of the original findings.

Until some of that exists, the accurate description of ornithine in cancer is the one at the top of this page: context-dependent, bidirectional, and untested in people.

References

  1. Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer.
    Bell HN, et al. Cell Metabolism. 35:134–149.e6 (2023) — DOI. PMID 36528023. Ornithine dosing is reported only as “daily intraperitoneal injection of 10 mM ornithine” — a concentration with no stated injection volume, so no mg/kg and no human-equivalent dose can be derived. In the TripleMut model, ornithine alone did not significantly improve survival (P = 0.07).
  2. SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma.
    Elaimy AL, et al. JCI Insight. 9:e184826 (2024) — Open access. Dosing is given as “ornithine was delivered by i.p. injection in C57BL/6J mice or s.c. implantation in NSG mice at a concentration of 20 mM” — again a concentration without a volume, frequency or duration. Also the 48,476-patient cirrhosis cohort.
  3. Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment.
    Tharp KM, et al. Nature Cancer. 5:1045–1062 (2024) — DOI. PMID 38831058. 2 g/kg daily oral gavage did not independently alter PyMT tumour growth; ornithine removed the tumour-mass reduction associated with myeloid Tgfbr2 knockout; 0.5–4.5 mM impaired CD8 metabolic function and viability and reduced organoid killing.
  4. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia.
    Ushmorov A, Hack V, Dröge W. Cancer Research. 59:3527–3534 (1999). PMID 10416620. The dose reversal: 0.2 mg/day improved muscle respiratory-chain activity and redox measures; 20 mg/day significantly increased tumour size (P < 0.05).
  5. Characterization of the landscape of the intratumoral microbiota reveals that Streptococcus anginosus increases the risk of gastric cancer initiation and progression.
    Yuan L, Pan L, Wang Y, et al. Cell Discovery. 10:117 (2024) — Open access. PMID 39587089. Separately administered ornithine promoted gastric-cancer xenograft growth. Dose, route, schedule and sample size for that arm could not be verified from the inaccessible supplement.
  6. Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in ARID1A-deficient triple negative breast cancer.
    Pan S, et al. Nature Communications. 17:6863 (2026) — Open access. Ornithine 100 µM increased PMN-MDSC proportions in culture; 10 mg/kg i.p. daily for 14 days increased them in bone marrow and bone-metastatic tumours. Ornithine did not directly increase cancer-cell colony formation or migration.
  7. Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse.
    Gonzalez & Byus. Cancer Research. 51:2932–2939 (1991). PMID 1903327. Arginine restriction reduced papillomas by about 40–50%; 2% ornithine in drinking water reversed that reduction. Abstract.
  8. Parenteral nutrition substitution studies.
    Grossie et al. (1992) — DOI, PMID 1619938; Grossie (1996) — DOI, PMID 8844725; Grossie & Nishioka (1997) — DOI, PMID 8970190. Ward colon tumours in parenterally fed rats; ornithine replacement avoided the extra growth induced by arginine-containing TPN but did not reduce tumours below chow controls. Groups of four to six. Abstracts.
  9. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer.
    Lee MS, Dennis C, Naqvi I, et al. Nature. 616:339–347 (2023) — DOI. PMID 36991126. Pancreatic tumours run OAT forward to manufacture ornithine from glutamine under arginine depletion; inhibiting OAT collapses polyamines and suppresses growth. The verified growth rescue was with putrescine.
  10. Reprogramming neuroblastoma by diet-enhanced polyamine depletion.
    Cherkaoui et al. (2025) — DOI. Isotope tracing and quantitative modelling identified circulating ornithine as an important tumour precursor, with much arginine-to-ornithine conversion occurring outside the tumour — a contrast with local synthesis in pancreatic cancer.
  11. Ornithine and cytotoxic T lymphocytes: the 1985–1991 series.
    Dröge et al., J Immunol 134:3379 (1985) — DOI, PMID 3920317; Jänicke & Dröge (1985) — DOI, PMID 3158402; Susskind et al. (1986) — DOI, PMID 2944613; Susskind et al. (1991) — DOI, PMID 1899361. Suppression of CTL activation and maturation at 9–10 mM; D-ornithine did not reproduce the effect; LAK activity was not equally suppressed. These records rest on abstracts, and the concentrations are high relative to anything oral supplementation would be expected to produce.
  12. Arginase 1 is a key driver of immune suppression in pancreatic cancer.
    Menjivar et al. eLife (2023) — Open access. PMID 36727849. 1.15 mM ornithine for 72 h partially restored CD8 proliferation in arginine-free medium but not activation, with no enhancement in arginine-replete medium.
  13. Ornithine metabolism in normal subjects and patients with cancer.
    Webber MM, et al. Journal of Nuclear Medicine. 21:1194–1196 (1980). PMID 6777468. The only documented human administration in this context: 8 µCi L-[1-14C]ornithine hydrochloride, 160 nanomoles intravenously, in ten untreated cancer patients and twelve volunteers. A tracer study, not a treatment.
  14. Ornithine and breast cancer: a matched case-control study.
    Zhang et al. Scientific Reports. 10:15502 (2020) — Open access. PMID 32968187. 735 cases and 735 controls; adjusted OR per SD 0.88 (0.79–0.97). 95% of controls had benign breast lumps; samples were taken after disease developed; ornithine users were excluded.
  15. Circulating amino acid levels and colorectal cancer risk in the EPIC and UK Biobank cohorts.
    Rothwell et al. BMC Medicine (2023) — Open access. The prospective entry: 654 future cases and 654 controls, OR per SD 0.88 (0.69–1.13), and 1.03 (0.78–1.36) excluding the first ten years. No significant association.
  16. Contradictory observational series.
    Hu et al. (2016), IUBMB Life — DOI, ornithine higher in breast cancer, 33 versus 32. Hu et al. (2021), Oncologie, ornithine lower in colon cancer, 63 versus 63. Coradduzza et al. (2023), IJMS 24:101 — Open access, ornithine higher in colorectal cancer, 50 versus 52, with cases substantially older than controls. Liu et al. (2024), Clinical Nutrition — DOI, PMID 38776618, higher ornithine with lower bladder cancer odds. Giorgione et al. (2026), higher than controls in bladder cancer, 14 patients.
  17. An NMR-based metabolic signature to identify clinically significant prostate cancer in patients undergoing biopsy.
    Ladurner et al. J Clin Endocrinol Metab (2025; online 2024) — DOI. PMID 39383254. 1,078 men; ornithine 63.7 versus 50.3 µM in significant disease. The reported 0.84 AUC belongs to a multi-metabolite and clinical model, not to ornithine alone.
  18. Causal association between metabolites and upper gastrointestinal tumors: a Mendelian randomization study.
    (2024) — DOI. PMID 39370813. In a 1,400-metabolite screen, genetically proxied ornithine associated with lower oesophageal cancer odds, OR 0.72 (0.563–0.936), P = 0.013, 28 instruments. Nominal exploratory result; ornithine was not functionally validated in the paper's cell experiments, and lifelong genetically influenced concentration is not equivalent to supplementation.
  19. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Goh ET, et al. Cochrane Database of Systematic Reviews. CD012410 (2018) — Cochrane. 36 trials, outcome data from 29 trials and 1,891 participants. All benefits disappear when restricted to trials at low risk of bias; certainty graded very low throughout; 17 trials industry-funded and 10 unpublished trials unavailable.
  20. Ocera Therapeutics top-line results, STOP-HE phase 2b study of OCR-002 in hepatic encephalopathy.
    Company announcement, 30 January 2017 — Release. 231 patients; primary endpoint missed (47 versus 64 h, p = 0.129); ammonia reduced 30.8 versus 11.8 µM (p = 0.017). Cited from the company announcement; the trial was subsequently published and I have not read the peer-reviewed report.
  21. Intravenous versus oral L-ornithine-L-aspartate in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A, Singh S, Jana S, et al. Scientific Reports. 14:11862 (2024) — Open access. 40 patients, 30 g/day by either route; ammonia fell 55.4 ± 32.58 versus 60.75 ± 13.82 µM (p = 0.511).
  22. The narrow-authorship advocacy literature.
    Butterworth RF. Metabolic Brain Disease. 35:75–81 (2020) — DOI. Six trials, 384 patients, RR 0.38 (0.23–0.62); single-author review. And Butterworth RF, Canbay A. Digestive Diseases. 37:63–68 (2019) — DOI, the source of the 463-patient uncontrolled observational data and the 72-patient open-label study in fatty liver.

Additional cell-culture, tracer, computational and smaller observational studies informing this page are not individually listed above. Several entries in the underlying inventory rest on abstracts rather than full texts, and several doses could not be recovered from the source papers; those limits are noted in the text wherever a claim depends on them.

Last updated: 7 October 2026. Literature searched through 7 October 2026.

No comments:

Post a Comment